No abstract available.
Amyloid Neuropathies* ; Amyloid*

No abstract available.
Amyloid ; Purpura

No abstract available.
Amyloid Neuropathies* ; Amyloid* ; Humans ; Prealbumin*

No abstract available.
Cerebral Amyloid Angiopathy ; Inflammation

Amyloid Neuropathies, Familial ; Humans

Humans ; Amyloidosis ; Amyloid ; Cardiomyopathies

Alzheimer's disease(AD) is a progressive dementia characterized by global cognitive decline and is defined pathologically by amyloid plaques and neurofibrillary tangles. In the past 10 years, important progress has been made in the understanding of the pathogenic mechanism of AD, and new therapeutic targets have become available that should allow the underlying disease process to be tackled directly. In this respect, the 'amyloid hypothesis' has been become the dominant theory in the cause of AD. New strategies for conquering the AD include attempts to stop the production of beta-amyloid protein(Abeta), increasing Abeta clearance, or interfere with Abeta aggregation and precipitation into fibril or plaques. This review summarizes recent advances in research on AD and inspects the perspective of research in potential therapies of AD.
Aged ; Alzheimer Disease* ; Amyloid ; Dementia ; Humans ; Neurofibrillary Tangles ; Plaque, Amyloid

We examined the amyloid deposit in various malignant cutaneous epithelial tumors by using Dylon stain. Histochemically identifiable amyloid deposits associated with basal cell epitheliomas(BCEs), squamous cell carcinomas(SCCs) and Bowens diseases were studied with monoclonal cytokeratin antibodies and anti-amyloid P antibodies. The results were as follaws, l. Amyloid deposits were detected in 5 of 12 BCEs, 4 of 11 SCCs, 3 of 9 Bowens diseases and 1 of 8 actinic keratoses. Amyloid deposits were not detected in o keratoacanthomas, 2 verrucous carcinomas, 1. Pagets disease and 3 extramammary Pagets diseases. 2. Anti-keratin antibody 34BE12 and anti-amyloid P antibody reacted with amyloid deposits in 3 of 5 BCEs which showed abundant amyloid deposits by Dylon stain. 3. Of 4 SCCs which showed amyloid deposits by Dylon stain, anti-keratin ant.ibody 34pE12 reacted with amyloid deposits in 2 cases and anti-amyloid P antibody reacted with amyloid deposits in 3 cases. 4. Anti-amyloid P antibody reacted with arnyloid deposits in 3 of 3 Bowens diseases which showed arnyloid deposits by Dylon stain. Anti-keratin antibody 34pE12 reacted with amyloid deposits only 1 of them. These findings suggest that epidermal keratins are the percursor substance of amyloid in malignant cutaneous epithelial tumors. The difference of antikeratin staining pattern between BCE-associated amyloid and SCC or Bowens disease-associated amyloid may be the results of difference in development stage of cutaneous amyloids.
Amyloid* ; Antibodies ; Carcinoma, Verrucous ; Keratins ; Keratoacanthoma ; Keratosis, Actinic ; Plaque, Amyloid*

Secondary localized cutaneous amyloidosis appears in association with a variety of inflammatory skin diseases and skin tumors. The presence of dermal amyloid deposits in lesions of porokeratosis has rarely been described in the literature. We describe a Korean case of disseminated superficial porokeratosis, with clear histologic evidence of amyloid deposition in the upper dermis.
Amyloid* ; Amyloidosis ; Dermis ; Plaque, Amyloid* ; Porokeratosis* ; Skin ; Skin Diseases

Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of beta-amyloid peptides (Abeta from the brain. Additionally, strategies for blocking tau hyperphosphorylation and aggregation have been suggested, including the development of drugs that can block the formation of tangles. However, there are no true disease-modifying drugs in the current market, though many drugs based on theories other than Abeta and tau pathology are under development. The purpose of this review was to provide information on the current development of AD drugs and to discuss the issues related to drug development.
Alzheimer Disease ; Amyloid ; Brain ; Dementia ; Neurofibrillary Tangles ; Peptides ; Plaque, Amyloid